Treatment
Cetuximab clinical trials
We’re tracking 136 recruiting studies that include Cetuximab, each written for real people, not researchers, below.
Recruiting studies
- NCT07257653RecruitingPhase 2
Cetuximab beta plus fruquintinib with or without immunotherapy for first-line advanced colorectal cancer
This trial tests a combination of two targeted drugs (cetuximab beta and fruquintinib) with or without an immunotherapy drug for people with a specific type of advanced colorectal cancer that has not been treated before. It aims to see if this approach is safe and effective for those whose tumors have certain genetic markers (RAS and BRAF wild type).
Hangzhou, ZhejiangAges 10–85 - NCT06935188RecruitingPhase 2
Dalpiciclib plus cetuximab for certain head and neck cancers
This trial tests a new combination of two drugs (dalpiciclib and cetuximab) versus cetuximab alone for people with head and neck cancer that is HPV-negative, has not responded to prior immunotherapy, and is not curable with surgery. The goal is to see if the combination works better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07813468RecruitingPhase 1
Cetuximab injection study in healthy men
This study tests a new version of the cancer drug cetuximab to see how it compares to the approved version (Erbitux) in healthy men. It helps ensure the new version works the same way in the body.
Haikou, HainanAges 18–46 - NCT07789210RecruitingPhase 2
Neoadjuvant targeted therapy for BRAF-mutant colorectal cancer
This trial is testing a combination of two targeted drugs (encorafenib and cetuximab) with standard chemotherapy before surgery in people with a specific type of colorectal cancer that has the BRAF V600E mutation and is locally advanced or has limited spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT07581912RecruitingPhase 2
Fulzerasib Plus Cetuximab for Advanced Colorectal Cancer With KRAS G12C
This trial tests a combination of two drugs (fulzerasib and cetuximab) given before surgery to shrink locally advanced colorectal cancer that has a specific genetic mutation called KRAS G12C. The goal is to help make the cancer easier to remove surgically and improve outcomes.
Hangzhou, ZhejiangAges 18–85 - NCT07506109RecruitingPhase 2
Study of sintilimab, ipilimumab, cetuximab, and dabrafenib for advanced colorectal cancer
This trial tests a combination of four drugs for people with a specific type of advanced colorectal cancer that has a BRAF V600E mutation and is microsatellite stable. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06640166RecruitingPhase 2
Encorafenib + Cetuximab with FOLFIRI after progression
This trial tests adding a new chemotherapy regimen (FOLFIRI) to the combination of Encorafenib and Cetuximab for people with a specific type of advanced colorectal cancer that has started growing again after initial treatment with Encorafenib and Cetuximab. The goal is to see if the new combination can help control the cancer longer.
MilanAges 18 years+ - NCT06959589Enrolling by invitationPhase 2
Combination therapy for KRAS G12C mutated colorectal cancer
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
Hangzhou, ZhejiangAges 18–75 - NCT06279351RecruitingPhase 2
Thalidomide plus standard chemo and cetuximab for left-sided colon cancer
This trial tests whether adding the drug thalidomide to standard chemotherapy plus cetuximab can work better for people with advanced left-sided colorectal cancer that hasn't been treated before. If you have a specific gene type (RAS/BRAF wild-type) and are in generally good health, this study may be an option.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05985954RecruitingPhase 1
Ulixertinib with cetuximab for colorectal cancer
This trial tests whether the drug ulixertinib, combined with cetuximab (and sometimes encorafenib), can help people with advanced or metastatic colorectal cancer who have already tried EGFR or BRAF-targeted therapy. It aims to find new treatment options for these patients.
Houston, TexasAges 18 years+ - NCT05959356RecruitingPhase 2
First-line treatment for left-sided metastatic colon cancer with specific tumor markers
This Phase 2 trial tests a combination of medicines (cetuximab, envafolimab, and chemotherapy) as the first treatment for certain left-sided metastatic colorectal cancers. It may help by slowing or shrinking the cancer in people whose tumor has no RAS/BRAF mutations and is microsatellite-stable (MSS).
Foshan, GuangdongAges 18 years+ - NCT04966481RecruitingPhase 3
Palbociclib plus cetuximab versus cetuximab alone
This trial studies whether adding palbociclib to cetuximab works better than cetuximab by itself for head and neck cancer that is growing again after an anti–PD-1/PD-L1 treatment. It is for people whose tumor has a specific gene change (CDKN2A loss) and who have not had too many prior treatments.
Worthington, MinnesotaAges 18 years+ - NCT04673955Recruiting
Real-world treatment study for metastatic bowel cancer with BRAF mutation
This real-world study looks at how doctors’ standard treatment works for metastatic colorectal cancer that has a specific BRAF mutation (BRAF V600E). It focuses on patients who are already starting—or will soon start—encorafenib plus cetuximab, using routine care rather than extra trial treatment.
Braunau am Inn, Upper AustriaAges 18 years+ - NCT05962502RecruitingPhase 2
Cetuximab plus irinotecan for left-sided RAS/BRAF wild-type colon cancer
This Phase 2 trial tests whether adding cetuximab to irinotecan can control metastatic colorectal cancer that has returned or worsened after standard treatments. It targets people whose tumor is left-sided and shows “wild-type” RAS and BRAF genes on blood testing after prior therapy.
Guangzhou, GuangdongAges 18 years+ - NCT05260671RecruitingPhase 2
Penpulimab plus cetuximab for advanced head and neck cancer
This trial studies penpulimab (an immune medicine) combined with cetuximab (an antibody drug) for recurrent or metastatic squamous cell head and neck cancer that cannot be treated with surgery or radiation. It aims to shrink tumors and improve survival in people whose tumor shows a specific immune marker (PD-L1).
Changchun, JilinAges 18–80 - NCT06151743RecruitingPhase 2
Testing drug combo before throat cancer surgery
This trial tests a new combination of drugs (an immunotherapy called a PD-1 inhibitor, cetuximab, and platinum chemotherapy) given before surgery for advanced throat cancer that requires removing the voice box. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07790510RecruitingPhase 1/Phase 2
Study of HSK42360 with cetuximab for BRAF-mutated colorectal cancer
This trial tests an experimental drug (HSK42360-Na) combined with standard treatments (cetuximab with or without chemotherapy) for people with advanced colorectal cancer that has a specific BRAF mutation. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
BeijingAges 18 years+ - NCT06547203RecruitingPhase 2
Cetuximab, irinotecan, and toripalimab for right-sided colorectal cancer
This trial tests a combination of three drugs (cetuximab, irinotecan, and toripalimab) for people with advanced right-sided colon cancer that does not have certain gene mutations. It's for those whose cancer has gotten worse after standard treatments.
Guangzhou, GuangdongAges 18–80 - NCT07775287RecruitingPhase 3
Petosemtamab plus chemotherapy for advanced colorectal cancer
This study tests a new drug called petosemtamab combined with chemotherapy for people with advanced colorectal cancer that has not responded to one prior treatment. The trial aims to see if adding petosemtamab helps the cancer shrink or grow more slowly compared to adding a standard targeted therapy like cetuximab or bevacizumab.
Los Angeles, CaliforniaAges 18 years+ - NCT06603376RecruitingPhase 2
Drug combo for BRAF-mutated advanced colorectal cancer
This trial tests a combination of four drugs (irinotecan liposome, fluorouracil, folinic acid, vermofenib, and cetuximab) as a first treatment for people with advanced colorectal cancer that has a specific BRAF V600E mutation. It aims to see if this combination can shrink tumors or slow their growth.
ShanghaiAges 18–80 - NCT07722754RecruitingPhase 2
Combination therapy for advanced colorectal cancer
This trial tests a combination of four drugs—bevacizumab, sintilimab, cetuximab, and irinotecan—in people whose colorectal cancer has spread and hasn't responded to previous treatments. The goal is to see if this new mix can shrink tumors or slow the cancer's growth.
Guangzhou, GuangdongAges 18–75 - NCT07702032RecruitingPhase 3
Study of petosemtamab plus chemo for left-sided colorectal cancer
This trial tests a new drug (petosemtamab) plus standard chemo to see if it works better than the current standard (cetuximab plus chemo) for people with advanced left-sided colorectal cancer that has not been treated yet. It is for patients whose cancer cells have no RAS or BRAF mutations.
Hot Springs, ArkansasAges 18 years+ - NCT07678593RecruitingPhase 1/Phase 2
Study of a new drug combined with standard therapy for RAS-mutated cancers
This study tests a new drug (GFH276) combined with either cetuximab or chemotherapy for people with advanced solid tumors or pancreatic cancer that have a specific genetic change (RAS mutation). The goal is to see if this combination can shrink tumors or slow their growth.
Concord, New South WalesAges 18 years+ - NCT07659795RecruitingPhase 2
Study of VS-7375 for KRAS G12D colorectal cancer
This trial tests a new targeted pill, VS-7375, for people with a specific type of advanced colorectal cancer called KRAS G12D. It's for those who either haven't had treatment yet or whose cancer has worsened after prior therapy.
Los Angeles, CaliforniaAges 18 years+
What Cetuximab is being studied for
Conditions with recruiting Cetuximab studies.
Common questions
- Are there clinical trials studying Cetuximab?
- Yes. Clin2 currently lists 136 recruiting studies that include Cetuximab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cetuximab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cetuximab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cetuximab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.